arrow
Z

Zhaohui Jin

Mayo Clinic
H指数:30
被引数:4,489

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma

II期研究: futibatinib联合pembrolizumab治疗FGF19表达型晚期肝细胞癌患者的疗效观察

2026-08-250
OAAI
Executive Summary of the American Radium Society Appropriate Use Criteria for the Use of Esophageal Stents in Patients With Esophageal Cancer

美国镭协会食管支架使用适当性标准执行摘要:食管癌患者中食管支架的应用

2025-12-010
PRE
First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study

一线阿替利珠单抗/贝伐珠单抗或度伐利尤单抗/特瑞普利单抗在晚期肝细胞癌中的应用:一项真实世界、多中心回顾性研究

2025-11-010
PRE
Study on the impact resistance performance of zeolite sphere substrate on simultaneous nitrification–denitrification process in sequencing batch biofilm reactor biofilm system: Effects of the C/N ratio

沸石球状载体对序批式生物膜反应器生物膜系统中同步硝化-反硝化过程抗冲击性能的影响研究:C/N比的影响

2025-10-170
PRE
Efficacy of perioperative and neoadjuvant therapies in gastric and gastroesophageal junction adenocarcinoma: a network meta-analysis

Anjum MU,Naqvi SAA,Jajja SA,Raina A,Afzal MU,Faisal KS,等. 围手术期及新辅助疗法在胃癌和胃食管结合部腺癌中的疗效:一项网络Meta分析. Oncologist. (2025) 30:oyaf157. doi: 10.1093/oncolo/oyaf157.

2025-08-011
OA
Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors

I期首次人体剂量递增研究的结果,该研究评估了第一类抗ILT2抗体SAR444881单药及联合pembrolizumab或cetuximab在晚期实体瘤患者中的疗效。

2024-09-010
PRE
Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting
2024-01-014
PRE
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium
2023-12-162
OAAI